Appeal No. 2006-0185 Page 2
Application No. 10/159,253
the resulting article acts to prevent the attachment of pathogenic yeast or other pathogenic
fungi to the wearer’s skin during use.” Page 3, lines 17-22. In a preferred embodiment,
the specification also states that “[t]he isoprenoid compound can be applied to the article
in solution at a concentration of between about 0.001% and about 2% by weight of the
solution.” Page 3, line 22 – page 4, line 4. Also, “suitable personal care articles include,
but are not limited to…health care articles, such as medical care articles, dental care
articles, veterinary care articles, bandages, and wound dressings…[and] include pre-
moistened wipes, absorbent wipes, bath tissue, facial tissue, lotions, and creams.” Page
15, lines 11-22.
Discussion
1. Claim construction
Claims 1, 3-6, 8-24, and 26-57 are pending. Since Appellant has not argued the
claims separately, they will stand or fall together. See 37 CFR 41.37(c)(1)(vii). We will
focus on claim 1 as the representative independent claim; claims 3-6, 8-24, and 26-57
will stand or fall with claim 1. Claim 1 reads as follows:
1. A personal care absorbent article, comprising:
a personal care absorbent article substrate; and
an isoprenoid compound comprising at least one of the group
consisting of farnesol, atlantol, (-)alpha-bisabolol, spathulenol, borneol,
trans-pinocarveol, and combinations thereof; wherein the isoprenoid
compound is applied to at least a skin-contacting surface of the substrate in
an amount effective to inhibit pathogenic fungi attachment to skin; and
wherein the pathogenic fungi comprises at least one of the group
consisting of Candida albicans, Mallessia, Tricophyton, Epidermophyton,
Scytalidium, Fusarium, Acremonium, Aspergillus, Scopulariopsis, and
Pityrosporum.
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 Next
Last modified: November 3, 2007